Repare unveils scale of layoffs with 75% of staff and chief medical officer heading for exit

For the last six weeks, the shadow of potential layoffs has hung over Repare Therapeutics’ employees. Monday, staff learned that three-quarters of them are heading for the exits.

The biotech’s leadership revealed in early January that it has been taking another look at its portfolio and found more candidates it's willing to part ways with. Chief among them was a combination of the biotech’s PKMYT1 inhibitor lunresertib and ATR inhibitor camonsertib, dubbed Lunre+Camo.